𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate

✍ Scribed by Jeffrey A. Zonder; Charles A. Schiffer

Publisher
Current Science Inc.
Year
2006
Tongue
English
Weight
292 KB
Volume
1
Category
Article
ISSN
1558-8211

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Acute myeloid leukemia developing during
Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities
✍ Attaphol Pawarode; Sheila N.J. Sait; Alain Nganga; Lionel J. Coignet; Maurice Ba πŸ“‚ Article πŸ“… 2007 πŸ› Elsevier Science 🌐 English βš– 171 KB

The BCR/ABL tyrosine kinase inhibitor imatinib mesylate produces a high rate of cytogenetic responses in patients with Philadelphia (Ph)-positive chronic myeloid leukemia (CML), but secondary clonal chromosome abnormalities may develop in Ph-negative cells, and acute myeloid leukemia (AML) has been